\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
Minimal residual disease analysis study of the ADAPT triad to evaluate the association between circulating tumor DNA positivity (ctDNA) and recurrence intervals
MADISON, Wis. , Aug. 2, 2022 /PRNewswire/ — Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnosis, announced that it has signed a collaboration agreement with the West German Study Group (WSG), a global study establishment focused on practice-changing breast cancer clinical trials. Together, Exact Sciences and WSG plan to conduct a multicenter prospective validation study in patients with her2-negative hormone receptor (HR)-positive early breast cancer. The study aims to demonstrate the ability of Exact Sciences’ tdNA liquid biopsy test to stumble upon minimal residual disease (MRD) and collect vital follow-up data and long-term outcomes.
The combined research, called ADAPT Triad, is expected to gain the knowledge of approximately 3000 German patients enrolled in two ongoing WSG ADAPT trials and one examination of the WSG registry. All patients included in the research are stratified according to the Oncotype DX Breast Recurrence Score®. The study is part of Exact Sciences’ global initiative to generate clinical validation data for its newly developed ctDNA MRD liquid biopsy test.
“This assignment of ADAPT Triad with WSG provides a great opportunity to help make treatment decisions and monitor recurrence and ultimately improve long-term outcomes for breast cancer patients,” said Rick Baehner, MD, Medical Director of Precision Oncology for Exact Sciences. In addition to helping validate our MRD test, we also look to the future to better understand the prospective synergies involving the predictive and forecast data provided through our Oncotype DX Breast Recurrence Score® test. WSG’s expertise in breast cancer studies makes them ideal collaborators to achieve those vital MRD Studies in HR-positive and HER2-negative early breast cancer.
The ADAPT Triad MRD analytical study in breast cancer is based on Exact Sciences and the National Surgical Adjuvant Breast and Bowel Project ‘NSABP) correct-MRD ii clinical validation study for tripping over MRD in colorectal cancer patients. These studies will create a strong evidence base for Exact Sciences’ MRD program in two major types of cancers in which the company has established its leadership.
“WSG’s ADAPT examination program is examining tactics to achieve patient-specific decision-making for early breast cancer treatment based on biomarkers,” said Professor Nadia Harbeck, WSG’s chief scientific officer and director of the breast center at LMU Klinikum Munich, Germany. Partnering with our longtime collaborators at Exact Sciences to compare the combination of post-initial, pre-recurrence cDNA treatment with the remote recurrence-free period is a valuable addition to our program and will help modify the treatment and follow-up program of forged tumors. . “
About minimal residual disease Minimal residual disease (MRD) refers to the presence of tumor-specific DNA in the picture after cancer treatment. These fragments of genetic data, known as circulating tumor DNA (cTDNA), are excreted in the blood through forged tumors as a component of the tumor expansion cycle. Its presence would possibly imply that a tumor is very likely to return. Solid tumors are usually not detected until they are complex enough to be detected through a radiological symbol or medical examination. Screening for ctDNA at incredibly low levels has the potential to provide very important information that can help uncover cancer recurrence in the past and tell treatment decisions.
This technique identifies somatic genomic alterations in DNA extracted from the patient’s tumor tissue and finds a subset of those mutations in the ctDNA present in the patient’s blood. before and after cancer treatment. This data can be used to inform decisions about adjuvant treatments and/or to monitor cancer recurrence, along with other clinical outcomes, offering more than 12 million verification opportunities in the United States alone. 1
About Exact Sciences Corp. A leading provider of cancer screening and diagnostic testing, Exact Sciences is tirelessly seeking smarter answers that provide the clarity needed to take life-changing movements sooner. Leveraging the good fortune of the Cologuard® and Oncotype® tests, Exact Sciences invests in its product portfolio to help patients before and in their cancer diagnosis and treatment. Exact Sciences brings together visionary collaborators to advance the fight against cancer. For more information, visit the company’s online page on www. exactsciences. com, join Exact Sciences on Twitter @ExactSciences, or search for Exact Sciences on Facebook.
About the West German Study Group and ADAPTThe West German Study Group (WSG) is a collaborative educational studies organization that focuses on the design, organization, and implementation of clinical trials in the breast cancer landscape. His ADAPT studies aim to expand new healing methods that especially improve efficacy and protection compared to existing popular therapies. Her clinical work focuses on the individualization of breast cancer treatment and the progression of deactivated healing methods to find the most productive treatment imaginable for each patient. More than 12,000 patients have already done so. participated in the WSG studies.
NOTE: Oncotype, Oncotype DX and Oncotype DX Breast Recurrence Score are or are registered by Genomic Health, Inc. Exact Sciences and Cologuard are or are registered by Exact Sciences Corporation. All other marks and service marks are the assets of their respective owners.
Forward-Looking Statements This press release contains forward-looking statements regarding our long-term expectations, anticipations, intentions, ideals or practices. These forward-looking statements are based on assumptions made by us as of the date hereof and are subject to known and unknown risks and uncertainties that may also cause actual results, situations and events to differ materially from those anticipated. There can be no assurance that WSG’s ADAPT MRD research study will effectively validate Exact Sciences’ MRD verification or that Exact Sciences will be able to effectively expand or commercialize any MRD or recurrence tracking verification. Accordingly, you deserve not to place undue reliance on forward-looking statements. Risks and uncertainties that may also be only our forward-looking statements are described in the Risk Factors sections of Exact Sciences’ most recent annual report on Form 10-K and future quarterly reports on Form 10-Q, as well as in other reports. presented through Exact Sciences. with the Securities and Exchange Commission. Exact Sciences disclaims any legal responsibility to publicly update any forward-looking statements, written or oral, that may be made from time to time, whether as a result of new information, long-term expansions or otherwise.
Exact Sciences USA Media Contact: Steph Spanos, sspanos@exactsciences. com, 608-556-4380International Media Contact: Federico Maiardi, fmaiardi@exactsciences. com, 41-79-138-1326Investor Contact: Megan Jones, meganjones@exactsciences. com, 608-535-8815
WSG Press Contact: Michael Städele, Michael. Staedele@wsg-online. com, 216156623 10
1 Source: U. S. Census data, Exact Science estimates; U. S. markets only. USA
Watch the multimedia content to download: https://www. prnewswire. com/news-releases/exact-sciences-and-west-german-study-group-announce-new-study-to-validate-detection-of-minimal-residual-disease-in-patients-with-breast-cancer-in-early-stage-301598380. html
SOURCE EXACT SCIENCES CORPORATION